Companies ›Healthcare ›347850.KQ

347850.KQ — KOSDAQ Biotechnology & Medical Research

DND PharmaTech Inc

$76 000,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

-791,0 %

ROE

-29,6 %

Net margin

-548,1 %

Debt / equity

0,08

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

DND PharmaTech Inc is a biotechnology and medical research company that operates within the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.

Business. DND PharmaTech Inc (347850.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the KOSDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-29,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 347850.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 347850.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

DND PharmaTech Inc (347850.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the KOSDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

DND PharmaTech Inc maintains a strong liquidity position, with a current ratio of 9.41, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to 32,883,741,890 KRW, which is a substantial portion of its total assets of 97,539,472,150 KRW. However, the company's liquidity is not supported by strong operating cash flow, which is negative at -21,138,952,810 KRW.

The company's profitability is weak, with a return on equity of -0.2963 and a return on assets of -0.2415, both significantly below the industry median for biotechnology firms. Operating income is negative at -33,992,611,600 KRW, and net income is also negative at -23,554,579,040 KRW. These figures suggest that the company is not currently generating sufficient revenue to cover its operating costs and is experiencing significant losses.

DND PharmaTech Inc's revenue is concentrated in the pharmaceuticals and medical research segments, with no disclosed geographic diversification in the provided data. The company's total revenue for the period is 4,297,604,950 KRW, but the absence of segment-specific revenue data limits the ability to assess the contribution of different business lines to overall performance.

The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. Analyst estimates suggest a mean revenue of 12,000,000,000 KRW, but the company's reported revenue is significantly lower at 4,297,604,950 KRW. The negative operating and net income figures indicate that the company is not currently on a path to profitability.

Risk factors for DND PharmaTech Inc include its negative operating cash flow and the absence of positive returns on equity and assets. The company's debt-to-equity ratio is 0.08, which is relatively low, but the negative free cash flow of -18,513,050,990 KRW suggests that the company may face challenges in maintaining its current capital structure without external financing. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.

Recent events and filings do not provide specific details on the company's operations or strategic direction. The absence of detailed disclosures in the provided data limits the ability to assess the company's recent performance and future prospects.

Key takeaways

DND PharmaTech Inc has a strong liquidity position but is experiencing significant operating and net losses.
The company's return on equity and assets is negative, indicating poor profitability.
Revenue is concentrated in the pharmaceuticals and medical research segments, with no geographic diversification disclosed.
Analyst estimates suggest a potential for revenue growth, but the company's current financial performance does not support this outlook.
The company's low debt-to-equity ratio is a positive, but the negative free cash flow may necessitate external financing.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$76 000,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$79.49B

Net cashⓘ

$26.64B

Current ratioⓘ

9.4

Debt / equityⓘ

0.1

ROAⓘ

-24.1%

ROEⓘ

-29.6%

Cash conversionⓘ

90.0%

CapEx / revenueⓘ

-1.5%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Operating income · consensus-26,0B KRW

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-791,0 %Below median

Net Margin-548,1 %Below median

ROE-29,6 %Below median

Capex / Rev-1,5 %Above P75

D/E0,08Below median

Cash Conv0,90Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

DND PharmaTech Inc Market data — financials · 2026-05-26
DND PharmaTech Inc Market data — analyst estimates · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

347850.KQCanonical

KOSDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread